Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis

Inclusion Criteria: * Outpatients with chronic bronchitis * Male or female subjects, \>=60 years old * Post bronchodilator forced expiratory volume in one second (FEV1) less than or equal to 60% predicted and FEV1 / forced vital capacity (FVC) less than 70% at enrollment * Documented history of 2 or more AECB episodes, within 12 months of study enrollment, requiring a course of systemic antibiotics and/or systemic corticosteroids * All symptoms/signs must be present and confirmed by the Investigator: * increase in dyspnea * purulent sputum * increase in sputum volume * Current or past cigarette smoker with equal to or greater than 20 pack year smoking history * Subjects must be exacerbation free for at least 30 days prior to enrollment * Subjects must be willing and able to complete the questionnaires and subject booklet without assistance Exclusion Criteria: * Known hypersensitivity to quinolones, ß lactams, or to any of the excipients of the study drugs * Known to have congenital or acquired QT prolongation * Known to have clinically relevant bradycardia * Known to have clinically relevant heart failure with reduced left ventricular ejection fraction * Known to have previous history of symptomatic arrhythmias * Taking QT prolonging drugs, for example Class Ia or III antiarrhythmic agents or other QT prolonging drugs * Known electrolyte disturbances that are not controlled, particularly uncorrected hypokalemia * Known history of hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose galactose malabsorption * History of a tendon disease/disorder * Known history of liver dysfunction (Child-Pugh C), including known elevated transaminase levels (alanine aminotransferase \[ALT\] and/or aspartate aminotransferase \[AST\] \>5 times the upper limit of normal \[5 x ULN\]) * Known severe renal impairment with glomerular filtration rate of \<30 mL/min * Known neutropenia (neutrophil count \<1000/mm3) caused by immunosuppressive therapy or malignancy * Known to have Acquired Immunodeficiency Syndrome (AIDS) (CD4 count of \<200/mm3), or be human immunodeficiency virus (HIV) positive and receiving highly active anti retroviral therapy (HAART) (testing for HIV is not mandatory) * Known chronic asthma (\>15% reversibility or at least 200 mL), bronchial carcinoma, active pulmonary tuberculosis, known diffuse bronchiectasis, cystic fibrosis, or pneumonia (a chest x ray is not mandatory) * Known history of chronic colonization of pathogenic organisms resistant to moxifloxacin and/or amoxicillin clavulanic acid (eg, P. aeruginosa, methicillin resistant Staphylococcus aureus) * Receiving long term (\>4 consecutive weeks) systemic corticosteroid treatment (\>10 mg/day of prednisolone or equivalent) * Received short course of systemic corticosteroid treatment within 30 days prior to enrollment * Life expectancy of less than 6 months * Receiving systemic antibacterial therapy within 30 days prior to study enrollment * Requiring concomitant systemic antibacterial agents * Requiring home ventilatory support (subjects requiring home/portable oxygen therapy or continuous positive airway pressure (CPAP) for sleep apnea are not excluded) and/or those who have a tracheotomy in situ * History of liver function disorders following previous treatment with amoxicillin-clavulanic acid * Receiving disulfiram therapy